About: Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $20.80 (+4.16%)
APLM NASDAQ Apollomics Inc. Class A Ordinary Shares
Apollomics Inc. Class A Ordinary Shares share price
Atividade de preço de APLM
Último preço
$ 20,800
Variação (24h)
0,83 USD (4,16%)
Volume
63.19K
Volume (média 4 sem.)
-
Abertura
$ 19,54
Variação do dia
$ 19,54 - $ 22,74
Fechamento anterior
$ 19,97
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
APLM price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals